CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies von Romanski, Annette, Uherek, Christoph, Bug, Gesine, Seifried, Erhard, Klingemann, Hans, Wels, Winfried S., Ottmann, Oliver G., Tonn, Torsten

Volltext

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma von Oelsner, Sarah, Friede, Miriam E, Zhang, Congcong, Wagner, Juliane, Badura, susanne, Bader, Peter, Ullrich, Evelyn, Ottmann, Oliver G, Klingemann, Hans, Tonn, Torsten, Wels, Winfried S

Volltext

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia von Gökbuget, Nicola, Zugmaier, Gerhard, Klinger, Matthias, Kufer, Peter, Stelljes, Matthias, Viardot, Andreas, Horst, Heinz A, Neumann, Svenja, Brüggemann, Monika, Ottmann, Oliver G, Burmeister, Thomas, Wessiepe, Dorothea, Topp, Max S, Bargou, Ralf

Volltext

Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation von Pfeifer, Heike, Raum, Katharina, Markovic, Sandra, Nowak, Verena, Fey, Stephanie, Obländer, Julia, Pressler, Jovita, Böhm, Verena, Brüggemann, Monika, Wunderle, Lydia, Hüttmann, Andreas, Wäsch, Ralph, Beck, Joachim, Stelljes, Matthias, Viardot, Andreas, Lang, Fabian, Hoelzer, Dieter, Hofmann, Wolf-Karsten, Serve, Hubert, Weiss, Christel, Goekbuget, Nicola, Ottmann, Oliver G., Nowak, Daniel

Volltext

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL von Kantarjian, Hagop, Giles, Francis, Wunderle, Lydia, Bhalla, Kapil, O'Brien, Susan, Wassmann, Barbara, Tanaka, Chiaki, Manley, Paul, Rae, Patricia, Mietlowski, William, Bochinski, Kathy, Hochhaus, Andreas, Griffin, James D, Hoelzer, Dieter, Albitar, Maher, Dugan, Margaret, Cortes, Jorge, Alland, Leila, Ottmann, Oliver G

Volltext

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies von Jabbour, Elias, Ottmann, Oliver G, Deininger, Michael, Hochhaus, Andreas

Volltext

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia von Badura, Susanne, Tesanovic, Tamara, Pfeifer, Heike, Wystub, Sylvia, Nijmeijer, Bart A, Liebermann, Marcus, Falkenburg, J H Frederik, Ruthardt, Martin, Ottmann, Oliver G

Volltext

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat von Oppliger Leibundgut, Elisabeth, Haubitz, Monika, Burington, Bart, Ottmann, Oliver G, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A, Röth, Alexander, Snyder, David S, Baerlocher, Gabriela M

Volltext

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells von Legut, Mateusz, Dolton, Garry, Mian, Afsar Ali, Ottmann, Oliver G., Sewell, Andrew K.

Volltext

Bim and Bad Mediate Imatinib-Induced Killing of Bcr/Abl⁺ Leukemic Cells, and Resistance Due to Their Loss Is Overcome by a BH3 Mimetic von Kuroda, Junya, Puthalakath, Hamsa, Cragg, Mark S., Kelly, Priscilla N., Bouillet, Philippe, Huang, David C. S., Kimura, Shinya, Ottmann, Oliver G., Druker, Brian J., Villunger, Andreas, Roberts, Andrew W., Strasser, Andreas

Volltext

TKI vs relapse after HSCT: is the jury still out? von Ottmann, Oliver G.

Volltext

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) von Ottmann, Oliver G, Pfeifer, Heike

Volltext

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia von Lang, Fabian, Wunderle, Lydia, Badura, Susanne, Schleyer, Eberhard, Brüggemann, Monika, Serve, Hubert, Schnittger, Susanne, Gökbuget, Nicola, Pfeifer, Heike, Wagner, Sebastian, Ashelford, Kevin, Bug, Gesine, Ottmann, Oliver G

Volltext

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells von Tanaka, Ruriko, Squires, Matthew S., Kimura, Shinya, Yokota, Asumi, Nagao, Rina, Yamauchi, Takahiro, Takeuchi, Miki, Yao, Hisayuki, Reule, Matthias, Smyth, Tomoko, Lyons, John F., Thompson, Neil T., Ashihara, Eishi, Ottmann, Oliver G., Maekawa, Taira

Volltext

Treatment of patients with advanced cancer with the natural killer cell line NK-92 von Tonn, Torsten, Schwabe, Dirk, Klingemann, Hans G, Becker, Sven, Esser, Ruth, Koehl, Ulrike, Suttorp, Meinolf, Seifried, Erhard, Ottmann, Oliver G, Bug, Gesine

Volltext

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) von Wassmann, Barbara, Pfeifer, Heike, Stadler, Michael, Bornhaüser, Martin, Bug, Gesine, Scheuring, Urban J., Brück, Patrick, Stelljes, Matthias, Schwerdtfeger, Rainer, Basara, Nadezda, Perz, Jolanta, Bunjes, Donald, Ledderose, Georg, Mahlberg, Rolf, Binckebanck, Anja, Gschaidmeier, Harald, Hoelzer, Dieter, Ottmann, Oliver G.

Volltext

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial von Döhner, Hartmut, Symeonidis, Argiris, Deeren, Dries, Demeter, Judit, Sanz, Miguel A., Anagnostopoulos, Achilles, Esteve, Jordi, Fiedler, Walter, Porkka, Kimmo, Kim, Hee‐Je, Lee, Je‐Hwan, Usuki, Kensuke, D'Ardia, Stefano, Won Jung, Chul, Salamero, Olga, Horst, Heinz‐August, Recher, Christian, Rousselot, Philippe, Sandhu, Irwindeep, Theunissen, Koen, Thol, Felicitas, Döhner, Konstanze, Teleanu, Veronica, DeAngelo, Daniel J., Naoe, Tomoki, Sekeres, Mikkael A., Belsack, Valerie, Ge, Miaomiao, Taube, Tillmann, Ottmann, Oliver G.

Volltext

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL von Rousselot, Philippe, Coudé, Marie Magdelaine, Gokbuget, Nicola, Gambacorti Passerini, Carlo, Hayette, Sandrine, Cayuela, Jean-Michel, Huguet, Françoise, Leguay, Thibaut, Chevallier, Patrice, Salanoubat, Celia, Bonmati, Caroline, Alexis, Magda, Hunault, Mathilde, Glaisner, Sylvie, Agape, Philippe, Berthou, Christian, Jourdan, Eric, Fernandes, José, Sutton, Laurent, Banos, Anne, Reman, Oumedaly, Lioure, Bruno, Thomas, Xavier, Ifrah, Norbert, Lafage-Pochitaloff, Marina, Bornand, Anne, Morisset, Laure, Robin, Valérie, Pfeifer, Heike, Delannoy, Andre, Ribera, Josep, Bassan, Renato, Delord, Marc, Hoelzer, Dieter, Dombret, Herve, Ottmann, Oliver G.

Volltext

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy von Döhner, Hartmut, Lübbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver G., Müller-Tidow, Carsten, Krämer, Alwin, Raffoux, Emmanuel, Döhner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger, Maertens, Johan

Volltext

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia von Baerlocher, Gabriela M, Oppliger Leibundgut, Elisabeth, Ottmann, Oliver G, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A, Röth, Alexander, Daskalakis, Michael, Burington, Bart, Stuart, Monic, Snyder, David S

Volltext